" The future challenge is to design and develop novel antiangiogenic nanomedicine that should exclusively target the cancer cells, "
Editorial Mukherjee
Antiangiogenic nanomaterials for cancer therapy Gold nanoparticles have long been used as cancer nanomedicine for their high biocompatibility, tunable size, easy synthesis, easy surface modifications, high drug loading and so on [12] . Mukherjee et al. showed the antiangiogenic property of 5 nm of spherical bare gold nanoparticles (AuNPs) for the first time [13] . The authors demonstrated that the AuNPs inhibit the activity of VEGF165 (HBGF) but do not interfere with the non heparin-binding VEGF121. Pan et al. recently observed that AuNPs inhibit the tumor angiogenesis by VEGF165-induced VEGFR2 and AKT phosphorylation. The authors also demonstrated the antitumor activity of AuNPs in mouse xenograft and ascites models [14] .
Silica and silicate-based nanoparticles have also been used for antiangiogenic cancer therapy. Setyawati et al. recently showed the size-dependent antiangiogenic therapy of mesoporous silica nanoparticles that cause production of intracellular reactive oxygen species activating the p53 tumor suppressor pathway [15] . This resulting signaling cascade causes restriction in endothelial cell proliferation, migration and invasion and eventually impedes the tumor growth [15] . Song et al. reported the antiangiogenic properties of copper nanoparticles, which inhibit HUVEC cell proliferation, tube formation and cell migration, causing cell cycle arrest in a dose-dependent manner [16] . Moreover, the copper nanoparticles inhibited the VEGFR2 expression in a dose-and time-dependent manner that is verified in the protein and mRNA level.
Grodzik et al. demonstrated the antiangiogenic activities of ultradispersed detonation diamond nanoparticles in a glioblastoma multiforme tumor model developed on a chorioallantoic membrane [17] . The authors further showed that treatments with detonation diamond nanoparticles are associated with the downregulation of FGF and VEGFR, confirming the antiangiogenic activity. Mukherjee et al. recently demonstrated the dose-dependent modulation of angiogenesis or antiangiogenesis by the treatment of reduced graphene oxides and graphene oxides upon controlling the reactive oxygen species [18] . While the low doses of graphene oxides and reduced graphene oxides upregulated the phosphorylation of AKT and VEGF, the high doses downregulated these signaling cascades triggering the antiangiogenesis. This was confirmed by endothelial cell proliferation assay, tube formation assay, wound scratching assay and chicken embryonic angiogenesis assay.
Giri et al. showed that nanoceria (NCe) nanoparticles exhibit antiangiogenic activities upon inhibition of VEGF165-induced HUVEC proliferation, capillary tube formation, phosphorylation of VEGFR2 and activation of MMP2 [19] . The authors further demonstrated that NCe inhibited the growth of ovarian tumor in a preclinical mouse model, which was confirmed by vascular endothelial cell apoptosis and reduced CD31 staining. Hence, NCe could be successfully used for antiangiogenic agent in ovarian cancer therapy. In another published report, Gurunathan et al. observed the antiangiogenic properties of biosynthesized silver nanoparticles (AgNPs) [20] . These AgNPs showed antiangiogenic properties, inhibiting VEGF-induced endothelial cell proliferation, capillary-like tube formation and cell migration. Moreover, AgNPs inhibited the new blood microvessels in the mouse Matrigel plug assay through the activation of PI3K/AKT pathways. Apart from metallic and nonmetallic nanoparticles, several polymer-based nanoparticles were also successfully investigated for antiangiogenic applications in cancer therapy including chitosan nanoparticles, lipid-based nanoparticles, tetrac nanoparticles and peptide nanoparticles [11, 21] .
Future perspective & challenges
The future challenge is to design and develop novel antiangiogenic nanomedicine that should exclusively target the cancer cells, without any side effects. Moreover, combination therapy using US FDA-approved chemotherapeutic drugs could help increase the anticancer efficacy of the antiangiogenic nanomaterials. Various issues need to be cautiously addressed before clinical implementation, including acute and chronic toxicity and pharmacokinetics and pharmacodynamics assessments of the nanomaterials, biodegradability and clearance of these nanomaterials, optimization of route of administration of dose, optimization of number of doses and frequency of doses, design of cost-effective and eco-friendly methods for the synthesis of antiangiogenic nanomaterials and strategies to combat drug resistance.
The distorted tumor vasculature offers adequate information for scientists to battle with to meet the challenges facing anticancer therapies. Special attention is necessary for effective antiangiogenic therapies in terms of metastasis, invasiveness and overall survival. With a rising number of antiangiogenic cancer agents being considered for clinical approval or approved, the call for biomarkers is vital for measuring safety and efficacy. The recent progress of nanobiotechnology offers paramount opportunities for researchers for the development of new-age technology to combat cancer. However, the future of antiangiogenic cancer treatment using nanomedicine needs additional
